Clinical Trial Update: Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 single-centre study assessing the antibody response to G17DT in patients with advanced pancreatic cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• G17DT

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Jaundice, Pancreatic Cancer | Phase 2 | Status: COMPLETED